Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …

JB Vermorken, J Stöhlmacher-Williams… - The lancet …, 2013 - thelancet.com
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …
被引用次数：496 相关文章
[PDF] academia.edu

[PDF][PDF] Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an …

JB Vermorken, J Stöhlmacher-Williams, I Davidenko… - 2013 - academia.edu
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …

JB Vermorken, J Stöhlmacher Williams… - THE LANCET …, 2013 - air.unimi.it
BACKGROUND: Previous trials have shown that anti-EGFR monoclonal antibodies can
improve clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma …

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open …

JB Vermorken, J Stöhlmacher-Williams… - The Lancet …, 2013 - pure.johnshopkins.edu
Background: Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …

JB Vermorken, J Stöhlmacher-Williams… - The Lancet …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …

JB Vermorken, J Stoelmacher-Williams… - LANCET …, 2013 - lib.ugent.be
Background: Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …

J Vermorken, J Stohlmacher-Williams, I Davidenko… - 2013 - digital.library.adelaide.edu.au
BACKGROUND: Previous trials have shown that anti-EGFR monoclonal antibodies can
improve clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma …
[PDF] core.ac.uk

[PDF][PDF] Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an …

JB Vermorken, J Stöhlmacher-Williams, I Davidenko… - Lancet Oncol, 2013 - core.ac.uk
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …

[引用][C] Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an …

JB Vermorken, J Stöhlmacher-Williams… - The Lancet …, 2013 - cir.nii.ac.jp
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic
squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 …

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …

JB Vermorken, J Stöhlmacher-Williams, I Davidenko… - Lancet Oncol, 2013 - thelancet.com
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …